GCP
ABCL icon

Gill Capital Partners’s AbCellera Biologics ABCL Stock Holding History

Gill Capital Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$785 Hold
100
– – ﹤0.01% 622
2026
Q1 		$349 Buy
+100
New +$360 ﹤0.01% 648

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Gill Capital Partners's ABCL Position: Q2 2026 in Review

Gill Capital Partners held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 100 shares worth $785. The position accounts for ﹤0.01% of the portfolio, ranked #622.

Gill Capital Partners first reported a position in ABCL in Q1 2026 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Gill Capital Partners held 100 shares of AbCellera Biologics worth $785 as of Q2 2026.
  • Gill Capital Partners left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #622 holding.
  • Gill Capital Partners first reported a position in AbCellera Biologics in Q1 2026 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.